Scientists from Nanyang Technological University, Singapore (NTU Singapore), have developed a new way to cure adhesives using a magnetic field.
Conventional adhesives like epoxy which are used to bond plastic, ceramics and wood are typically designed to cure using moisture, heat or light. They often require specific curing temperatures, ranging from room temperature up to 80 degrees Celsius.
The curing process is necessary to cross-link and bond the glue with the two secured surfaces as the glue crystallizes and hardens to achieve its final strength.
We interviewed a group of Russian biohackers who performed a plasma dilution experiment on themselves. This experiment, the first of its kind, was based on previous mouse studies by Drs. Irina and Michael Conboy.
Some molecules, while essential for various body functions, can be harmful when overproduced. Inflammatory cytokines, such as transforming growth factor beta 1 (TGF-ß1), interleukin 6 (IL6), and tumor necrosis factor alpha (TNFa) are good examples. The concentration of these cytokines in our blood rises with age, provoking inflammaging, the chronic inflammation that is associated with aging. It has been long speculated that reducing the harmful molecules in circulation can attenuate aging.
Preliminary results suggest anti-COVID19 nanobodies may be effective at preventing and diagnosing infections.
National Institutes of Health researchers have isolated a set of promising, tiny antibodies, or “nanobodies,” against SARS-CoV-2 that were produced by a llama named Cormac. Preliminary results published in Scientific Reports suggest that at least one of these nanobodies, called NIH-CoVnb-112, could prevent infections and detect virus particles by grabbing hold of SARS-CoV-2 spike proteins. In addition, the nanobody appeared to work equally well in either liquid or aerosol form, suggesting it could remain effective after inhalation. SARS-CoV-2 is the virus that causes COVID-19.
A generation after a NASA spacecraft’s probe found an unexpectedly hot and dense atmosphere at Jupiter, a newer agency mission may have some answers to the puzzle.
NASA’s Juno spacecraft discovered that these “hot spots” on the gas giant planet — which the Galileo spacecraft discovered in 1995 — are wider and deeper than previous models and observations suggest, according to results revealed Dec. 11 at the American Geophysical Union’s annual fall conference, held virtually this year due to the coronavirus pandemic.
One of the ongoing questions these past few months has been why so many tech products have been so hard to buy. We’ve made repeated reference to known potential factors like COVID-19, economic disruptions, yield issues, and the impact of scalping bots, but there’s a new argument for what’s causing such general problems across so many markets: Insufficient investment in 200mm wafers.
Today, leading-edge silicon is invariably manufactured on 300mm wafers. Over the past few decades, manufacturers have introduced larger wafer sizes: 100mm, 150mm, 200mm, and 300mm have all been common standards at one time or another. In the PC enthusiast space, 300mm wafers have long been considered superior to 200mm wafers, because the larger wafer size reduces waste and typically improves the foundry’s output in terms of chips manufactured per day.
There aren’t that many commercial foundries still dedicated to 150mm or smaller wafer sizes, but a number of foundries still run 200mm fab lines. TSMC and Samsung both offer the node, as well as a number of second-tier foundries. GlobalFoundries has 200mm facilities, as do SMIC, UMC, TowerJazz, and SkyWater. A great many IoT and 5G chips are built on 200mm, as are some analog processors, MEMS devices, and RF solutions.
Using CRISPR to alter the genetics of astrocytes in mice, researchers hope they’ve discovered how to regenerate neurons in patients with Parkinsons disease.
Using CRISPR/Cas9 gene editing tools, researchers introduced a common Parkinson’s disease mutation into stems cells of the marmoset monkey for a first time, paving the way toward a primate model of this disease.
As we approach the end of 2020, according to the U.S. National Cancer Institute (NCI), we have had approximately 1, 806, 590 new cases of cancer diagnosed in the United States, with 606, 520 deaths. Cancer continues to be the leading causes of death worldwide. In 2018, there were 18.1 million new cases and 9.5 million cancer-related deaths worldwide.
By 2040, the number of new cancer cases per year is expected to rise to 29.5 million and the number of cancer-related deaths to 16.4 million.
Dr. Azra Raza, MD, is the Chan Soon-Shiong Professor of Medicine, in the Department of Medicine, Division of Hematology / Oncology, and Director of the Myelodysplastic Syndrome (MDS) Center, at the Columbia University Medical Center.
Previously, Dr. Raza was the Chief of Hematology-Oncology and the Gladys Smith Martin Professor of Oncology at the University of Massachusetts.
Dr. Raza is an international authority on pre-leukemia / MDS, and acute leukemia, and is both a physician and scientist who divides her time equally between caring for patients and supervising a state-of-the-art basic research lab which is well-funded by multiple large grants. Dr. Raza started collecting blood and marrow samples on her patients in 1984 and now her Tissue Bank, the largest and oldest in the country with over 60, 000 samples, is considered a unique national treasure.
Dr. Raza has published her original clinical and basic research comprising over 300 peer-reviewed manuscripts in high profile journals like Nature, New England Journal of Medicine, Cell, Molecular Cell, Cancer Research, Blood, Leukemia.
The potential threat of biological warfare with a specific agent is proportional to the susceptibility of the population to that agent. Preventing disease after exposure to a biological agent is partially a function of the immunity of the exposed individual. The only available countermeasure that can provide immediate immunity against a biological agent is passive antibody. Unlike vaccines, which require time to induce protective immunity and depend on the host’s ability to mount an immune response, passive antibody can theoretically confer protection regardless of the immune status of the host. Passive antibody therapy has substantial advantages over antimicrobial agents and other measures for postexposure prophylaxis, including low toxicity and high specific activity. Specific antibodies are active against the major agents of bioterrorism, including anthrax, smallpox, botulinum toxin, tularemia, and plague. This article proposes a biological defense initiative based on developing, producing, and stockpiling specific antibody reagents that can be used to protect the population against biological warfare threats.
Defense strategies against biological weapons include such measures as enhanced epidemiologic surveillance, vaccination, and use of antimicrobial agents, with the important caveat that the final line of defense is the immune system of the exposed individual. The potential threat of biological warfare and bioterrorism is inversely proportional to the number of immune persons in the targeted population. Thus, biological agents are potential weapons only against populations with a substantial proportion of susceptible persons. For example, smallpox virus would not be considered a useful biological weapon against a population universally immunized with vaccinia.
Vaccination can reduce the susceptibility of a population against specific threats provided that a safe vaccine exists that can induce a protective response. Unfortunately, inducing a protective response by vaccination may take longer than the time between exposure and onset of disease. Moreover, many vaccines require multiple doses to achieve a protective immune response, which would limit their usefulness in an emergency vaccination program to provide rapid prophylaxis after an attack. In fact, not all vaccine recipients mount a protective response, even after receiving the recommended immunization schedule. Persons with impaired immunity are often unable to generate effective response to vaccination, and certain vaccines may be contraindicated for them (1). For example, the vaccine against hepatitis B does not elicit an antibody response in approximately 10% of vaccines, and the percentage of nonresponders is substantially higher in immunocompromised persons (1).
